A groundbreaking trial conducted by Memorial Sloan Kettering Cancer Center using an immunotherapy drug from GSK has shown remarkable success in treating solid tumors without resorting to traditional harsh therapies. Among 103 participants, the drug, dostarlimab, eliminated tumors in 49 patients with rectal cancer and 35 of 54 patients with other cancers, including stomach, esophagus, liver, endometrium, urinary tract, and prostate cancers. This approach offers hope for a subset of cancer patients who previously faced severe quality-of-life impacts from standard treatments.
— new from The New York Times
